Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
ZLAB Stock Chart & Stats
$18.42
-$1.34(-5.19%)
At close: 4:00 PM EST
$18.42
-$1.34(-5.19%)
Day’s Range― - ―
52-Week Range$15.96 - $44.34
Previous CloseN/A
Volume273.50K
Average Volume (3M)628.50K
Market Cap
$2.06B
Enterprise Value$1.51B
Total Cash (Recent Filing)$689.57M
Total Debt (Recent Filing)$224.26M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
May 12, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding112,812,805
10 Day Avg. Volume424,319
30 Day Avg. Volume628,503
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)2.70
Price to Sales (P/S)4.20
P/FCF Ratio-12.16
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue3.28
Enterprise Value/Gross Profit5.60
Enterprise Value/Ebitda-9.54
Forecast
1Y Price Target
$36.13Price Target Upside96.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$517.78M
Bulls Say, Bears Say
Bulls Say
Cost Discipline And Financial ResilienceAnalyst observes reduced research and selling expenses and a narrower net loss, indicating improved cost discipline that strengthens the company's ability to fund pipeline advancement.
Late-stage Clinical ProgressAnalyst highlights strong clinical progress across multiple late-stage drug candidates, including Zoci, supporting meaningful long-term upside from potential regulatory approvals.
New Product LaunchesAnalyst notes planned launches of newly approved therapies could generate new revenue streams and broaden commercial opportunities across multiple treatment areas.
Bears Say
Generic CompetitionAnalyst points to intense competition from Olaparib generics that is expected to erode market share and pressure sales in the PARP franchise.
Inventory Provisions And Margin WeaknessAnalyst highlights higher inventory provisions for a key product that weakened gross margin and reduced profitability on product sales.
Reimbursement And Pricing PressureAnalyst warns national reimbursement price cuts for core products like VYVGART could reduce pricing power and materially depress commercial revenues.
Zai Lab News
ZLAB FAQ
What was Zai Lab’s price range in the past 12 months?
Zai Lab lowest stock price was $15.96 and its highest was $44.34 in the past 12 months.
What is Zai Lab’s market cap?
Zai Lab’s market cap is $2.06B.
When is Zai Lab’s upcoming earnings report date?
Zai Lab’s upcoming earnings report date is May 12, 2026 which is in 70 days.
How were Zai Lab’s earnings last quarter?
Zai Lab released its earnings results on Feb 26, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.359 by -$0.101.
Is Zai Lab overvalued?
According to Wall Street analysts Zai Lab’s price is currently Undervalued.
Does Zai Lab pay dividends?
Zai Lab does not currently pay dividends.
What is Zai Lab’s EPS estimate?
Zai Lab’s EPS estimate is -0.47.
How many shares outstanding does Zai Lab have?
Zai Lab has 112,812,805 shares outstanding.
What happened to Zai Lab’s price movement after its last earnings report?
Zai Lab reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.359. Following the earnings report the stock price went up 1.547%.
Which hedge fund is a major shareholder of Zai Lab?
Currently, no hedge funds are holding shares in ZLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zai Lab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.13 (96.15% Upside)
$36.13 (96.15% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 198.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Very Bullish
Bullish news 91%
Bearish news 9%
Bearish news 9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.09%
12-Months-Change
Fundamentals
Return on Equity
-22.62%
Trailing 12-Months
Asset Growth
-1.13%
Trailing 12-Months
Company Description
Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
ZLAB Company Deck
ZLAB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and R&D momentum: double-digit revenue growth (Q4 +17%, FY +15%), a solid cash balance ($790M), improved operating leverage (R&D -6%, SG&A -12% Q4 / -7% FY), and rapid advancement of high-impact global programs (notably zoci's rapid move to Phase III and encouraging intracranial activity). Management also outlined several near-term commercial launches and late-stage regional catalysts. Offsetting these positives were near-term commercial and pricing headwinds (NRDL renewal effects, hospital procurement timing), supply constraints earlier in the year, generic competition in certain categories, and some uncertainty around 2026 guidance and regulatory/enrollment timing for global registrational programs. On balance, the highlights—particularly the strong financial momentum, large pipeline milestones, and robust cash runway—substantially outweigh the lowlights, though execution and regulatory risks remain.View all ZLAB earnings summariesZLAB Stock 12 Month Forecast
Average Price Target
$36.13
▲(96.15% Upside)
Technical Analysis
Ownership Overview
1.73% Insiders
11.22% Mutual Funds
5.47% Other Institutional Investors
80.62% Public Companies and
Individual Investors